CAB+RPV Long-acting injectables
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CAB+RPV Long-acting injectables, covering 2023-05-19 to 2023-05-19. Get the full timeline:
Most recent: Clinical Trial Update: A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries [Phase 3]